It is given once a day as a shot under the skin. Alhemo is a biologic medicine that blocks a protein called tissue factor pathway inhibitor (TFPI). This substance is normally made by your body ...

Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year. Marstacimab will be ...

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia. The recommendation by the EMA's ...

New Delhi: The pharmaceutical major Pfizer has got approval from the Subject Expert Committee (SEC) functional under the ...